UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVE	NTOR .	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/509,314	03/21/2005	In-Sup Noh	In-Sup Noh		5414
20583 JONES DAY	7590 01/22	/2008		EXAMINER	
222 EAST 41S				GHERBI, SUZETTE JAIME J	
NEW YORK, NY 10017				ART UNIT	PAPER NUMBER
·				3738	
		•			
				MAIL DATE	DELIVERY MODE
			•	01/22/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		c.7	
	Application No.	Applicant(s)	
Office Action Summary	10/509,314	NOH, IN-SUP	
Office Action Summary	Examiner	Art Unit	
The MAIL INC DATE of this service is also	Suzette J. Gherbi	3738	
The MAILING DATE of this communication Period for Reply	appears on the cover sheet with	the correspondence address	
A SHORTENED STATUTORY PERIOD FOR RE WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory per - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the meanned patent term adjustment. See 37 CFR 1.704(b).	S DATE OF THIS COMMUNICA R 1.136(a). In no event, however, may a reprince of the communication will expire SIX (6) MONTI atute, cause the application to become ABA	ATION. ly be timely filed 4S from the mailing date of this communication. NDONED (35 U.S.C. § 133).	
Status			
1)⊠ Responsive to communication(s) filed on 2 2a) This action is FINAL. 2b)⊠ T 3)□ Since this application is in condition for allocation accordance with the practice under	his action is non-final. wance except for formal matte	•	
Disposition of Claims			•
4) ⊠ Claim(s) 1-14 is/are pending in the applicate 4a) Of the above claim(s) 14 is/are withdraw 5) ⊠ Claim(s) 8-13 is/are allowed. 6) ⊠ Claim(s) 1-7 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and	vn from consideration.		
Application Papers			
9) The specification is objected to by the Exam 10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to a Replacement drawing sheet(s) including the cor 11) The oath or declaration is objected to by the	accepted or b) objected to by the drawing(s) be held in abeyand rection is required if the drawing(s	e. See 37 CFR 1.85(a).) is objected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority documents application from the International Bure * See the attached detailed Office action for a	ents have been received. ents have been received in Appriority documents have been recau (PCT Rule 17.2(a)).	plication No eceived in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	Paper No(s)	mmary (PTO-413) Mail Date ormal Patent Application	
Paper No(s)/Mail Date 10/20/04.	6) Other:		

DETAILED ACTION

Claim Objections

The numbering of claims is not in accordance with 37 CFR 1.126 which requires the original numbering of the claims to be preserved throughout the prosecution. When claims are canceled, the remaining claims must not be renumbered. When new claims are presented, they must be numbered consecutively beginning with the number next following the highest numbered claims previously presented (whether entered or not). Misnumbered claims 5-15 been renumbered 4-14.

Claim 14 is objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim should refer back to claims in the alternative form only and/or cannot depend from multiple dependent claims. See MPEP § 608.01(n). Accordingly, the claim 14 not been further treated on the merits.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Waksman et al. 6,355,055 in view of Tu et al. 5,061,276. Waksman et al. discloses the invention as claimed noting figures 2, and 4-4F comprising: A hybrid artificial blood vessel (10) comprising a biodegradable polymer supporting layer (see 4D and element 20) on at least one of an inside and an outside of a non-degradable artificial blood vessel layer, (12 see 2:61-62, 4:46-47) wherein a drug (40); , the biodegradable polymer-supporting layer, and the interface of the artificial blood vessel layer and the supporting layer.

However Waksman et al. does not specify that the drug is stored in at least one region selected from the group consisting of the microporous (22) space of the non-degradable artificial blood vessel layer.

Tu et al. teaches multi-layered tubes made from PTFE that have mircropores and are utilized for vascular grafts see (9:1-9 and 11:37-42). it would have been obvious to one having ordinary skill in the art at the time the invention was made to take the device of Waksman et al. and utilize a material such as PTFE which is well known for it's microporous properties for the substrate 12 because it would allow the drug layer to diffuse at controlled rates, further Waksman et al. does envision the use of micropores with respect to element 22.

Allowable Subject Matter

Claims 8-13 allowed.

Art Unit: 3738

Page 4

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Suzette J-J Gherbi whose work schedule is Maxi-Flex off every other Friday and whose telephone number is 571-272-4751.

The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0858.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SUZETTE GHERBI

PRIMARY EXAMINER

TECHNOLOGY CENTER 3700

16 January 2008